Navigation Links
Angiotech announces exclusive distribution agreement with B. Braun for Angiotech's proprietary Quill(TM) SRS product line
Date:5/3/2010

VANCOUVER, May 3 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ( ANPI, TSX: ANP), a specialty pharmaceutical and medical device company, today announced that it has entered into an exclusive distribution agreement with B. Braun for its proprietary Quill(TM) SRS product line in the United Kingdom, Ireland, and France. The term of the distribution agreement will be for five years.

According to The Royal College of Surgeons of England, there are approximately 4.2 million surgical operations carried out every year in England alone. There are more than 18,000 surgeons currently practicing in England in approximately 2,900 operating theaters. According to market research, in France there are over 5 million surgical procedures performed annually by more than 17,000 surgeons in excess of 3,300 hospital facilities.

"We are very excited and proud to have one of the leading companies in wound closure partner with Angiotech to facilitate the continued acceptance of Quill(TM) SRS in these critical European countries," said Dr. William Hunter, President and CEO of Angiotech. "Having a leading company such as B. Braun, with its long legacy of innovation and technology leadership, join us as one of our European partners further validates Quill(TM) SRS's market potential as a transformational technology in the surgical market."

"We are very much looking forward to including the Quill(TM) SRS knotless suturing system in our comprehensive Closure Technologies portfolio and start redefining wound closure. Such innovat
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Massachusetts (PRWEB) October 22, 2014 ... announced the release of a new infographic, Understanding ... to create a beautifully designed, easy to follow informative ... transmission, areas of outbreak, symptoms and prevention. , "As ... discovered that the 2014 Ebola outbreak represents not only ...
(Date:10/22/2014)... CA (PRWEB) October 22, 2014 ... from Sartorius, A & D Weighing, Rice Lake, ... CPA Semi-Micro Balance . The Sartorius CPA Semi-Micro ... an affordable high-quality, precise, and user-friendly laboratory balance. ... of laboratory equipment, their laboratory balances are well ...
(Date:10/22/2014)... Physicians Choice Laboratory Services (PCLS) ... which enables healthcare providers to individualize therapeutic treatments ... results, healthcare providers are better able to assess ... minimizing risks for adverse drug reactions and interactions. ... FDA [1] more than 2.2 million adverse drug ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... Inc. (Nasdaq: CALP ) today announced that ... will be webcast on Thursday,January 10, 2008 at ... of,Caliper, will be providing an update on the ... http://www.metameetings.com/webcasts/jpmorgan/healthcare08/ . An archived,presentation will be available for ...
... Md., Jan. 3 EntreMed, Inc.,(Nasdaq: ... for the treatment of cancer and inflammatory ... Drug Administration (FDA) has accepted its,Investigational New ... ENMD-2076., (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ), ...
... Sweden, January 3 Amic AB (Uppsala, Sweden),announced ... license under,patent rights of Roche Diagnostics to commercialise ... market., NT-proBNP is a key cardiac marker ... diagnosis and management of heart failure, and,risk stratification ...
Cached Biology Technology:EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076 2EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076 3
(Date:10/22/2014)... Oct. 20, 2014  Leading identity analyst firm Acuity ... of the world,s population will have a chip-based National ... Europe . Asia , with ... accounting for more than 60% of all National eID ... report  -- "The Global National eID Industry ...
(Date:10/18/2014)... stress and stress-related psychiatric disorders are associated ... the molecular mechanisms underlying this relation are ... the development of targeted preventive strategies and ... diseases. This work is presented at the ... Now an international group of researchers from ...
(Date:10/17/2014)... Rockville, MD – Accurate knowledge regarding Ebola is critical ... current risk of hazardous global outbreak and epidemic. The ... has launched a special issue, Ebola Virus and Public ... with necessary knowledge in this critical societal moment. ... Primer on Ebola for Clinicians . The primer was ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Researchers find why depression and aging linked to increased disease risk 2
... PHILADELPHIA Molecular biologist Jonathan Brody, Ph.D., ... Goney, Ph.D., research assistant professor, and member of ... in the Department of Pathology, Anatomy and Cell ... University have been awarded a W.W. Smith Charitable ...
... an important breakthrough, scientists at McMaster University have discovered how ... The discovery, published in the prestigious science journal Nature ... needing blood for surgery, cancer treatment or treatment of other ... created from a patch of their own skin to provide ...
... Philadelphia, Pa. Examining the blood "metabolomics" ... cigarette revealed activation of pathways involved in cell ... say researchers at Georgetown Lombardi Comprehensive Cancer Center, ... They say their findings, presented at the Ninth ...
Cached Biology News:Jefferson researchers receive W.W. Smith Charitable Trust 2Jefferson researchers receive W.W. Smith Charitable Trust 3Studying the metabolome of smokers, Lombardi researchers find early signs of damage 2
Protein Marker Detection Pack contains biotinylate...
JMJD2B Antibody...
Agarose, Biotechnology grade, 500g...
... proto-oncogene was first identified as the cellular homolog ... B and Jun D have been shown to ... regions, which are involved in dimerization and DNA ... in transcriptional activation, diverge. Antigen: ...
Biology Products: